CME in Minutes: Education in Gastroenterology

Please visit answersincme.com/FSP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jay N. Yepuri, MD, MS, FACG, FTSGE. In this activity, an expert in gastroenterology discusses molecular prognostics tests that predict the risk of progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC). Upon completion of this activity, participants should be better able to: Describe the limitations of traditional approaches to predicting risk of progression to EAC for patients with BE; Review the evolving role of advanced molecular prognostic tests in assessing risk of progression to EAC in patients with BE; and Outline multidisciplinary strategies to integrate advanced molecular prognostic tests into the management of patients with BE.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/AQE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nirmala Gonsalves, MD, AGAF, FACG. In this activity, an expert in esophageal gastroenterology, discusses strategies for pharmacological treatment of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Specify the current guideline recommendations for the pharmacologic treatment of eosinophilic esophagitis (EoE); Formulate personalized strategies to use approved pharmacologic options during initiation and maintenance phases of EoE management; and Apply multidisciplinary strategies to optimize long-term management of patients with EoE using approved pharmacologic treatments.

Please visit answersincme.com/860/103518989-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD and Chiara Cremolini, MD, PhD. In this activity, experts in metastatic colorectal cancer (mCRC) discuss real-world evidence and clinical insights related to durable responses and long-term benefits in later-line care. Upon completion of this activity, participants should be better able to: Propose treatment plans based on predictors of durable benefit and real-world evidence.

Please visit answersincme.com/860/102331945-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth Smyth, MD, FRCP and Daniela Molena, MD. In this activity, experts in gastric/gastroesophageal junction adenocarcinoma discuss the latest evidence and practical strategies for optimizing the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma with perioperative immunotherapy. Upon completion of this activity, participants should be better able to: Evaluate the evidence supporting the integration of perioperative immunotherapy (IO) in the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma; Analyze the role of biomarkers in decision-making for perioperative IO in resectable G/GEJ adenocarcinoma; and Outline multidisciplinary strategies for optimizing the care of patients receiving perioperative IO for resectable G/GEJ adenocarcinoma.